Price T Rowe Associates Inc Immuneering Corp Transaction History

Price T Rowe Associates Inc

$816 Billion
Q1 2024

A detailed history of Price T Rowe Associates Inc transactions in Immuneering Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 910,266 shares of IMRX stock, worth $1.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

910,266

Previous 3,378,100 73.05%

Holding current value

$1.3 Million

Previous $24.8 Million 89.4%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.91 - $7.32 $4.71 Million - $18.1 Million	-2,467,834 Reduced 73.05%	910,266 $2.63 Million
Q4 2023 Feb 14, 2024	SELL	$4.84 - $8.44 $751,274 - $1.31 Million	-155,222 Reduced 4.39%	3,378,100 $24.8 Million
Q3 2023 Nov 14, 2023	SELL	$7.21 - $10.68 $341,919 - $506,477	-47,423 Reduced 1.32%	3,533,322 $27.1 Million
Q2 2023 Aug 14, 2023	BUY	$6.49 - $13.36 $794,226 - $1.63 Million	122,377 Added 3.54%	3,580,745 $36.3 Million
Q1 2023 May 15, 2023	SELL	$3.78 - $10.38 $609,305 - $1.67 Million	-161,192 Reduced 4.45%	3,458,368 $33.6 Million

Q4 2022 Feb 14, 2023	SELL	$4.09 - $10.24 $179,681 - $449,863	-43,932 Reduced 1.2%	3,619,560 $17.6 Million
Q3 2022 Nov 14, 2022	SELL	$5.0 - $12.85 $2.4 Million - $6.16 Million	-479,337 Reduced 11.57%	3,663,492 $52.5 Million
Q2 2022 Aug 15, 2022	BUY	$3.89 - $7.81 $2.25 Million - $4.51 Million	577,356 Added 16.19%	4,142,829 $22.4 Million
Q1 2022 May 16, 2022	BUY	$6.47 - $16.99 $2.44 Million - $6.4 Million	376,968 Added 11.82%	3,565,473 $23.1 Million
Q4 2021 Feb 14, 2022	BUY	$16.12 - $31.02 $1.2 Million - $2.31 Million	74,480 Added 2.39%	3,188,505 $50.7 Million
Q3 2021 Nov 15, 2021	BUY	$17.0 - $32.84 $52.9 Million - $102 Million	3,114,025 New	3,114,025 $81.2 Million

Others Institutions Holding IMRX

# of Institutions

Shares Held

11.6M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $37.7M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Immuneering Corp Transaction History